Previous 10 | Next 10 |
Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled “ Points to consider in the preparation and transfusion of COVID-19 convalescent plasma .” The document w...
Cerus Corporation (Nasdaq: CERS) announced today that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP). Cerus’ field team supported the INTERCEPT system implementation which was completed in one week. ...
Gainers: IFRX +40.1% . CERS +9.9% . NVAX +8.3% . TWOU +4.7% . More news on: InflaRx N.V., Cerus Corporation, Novavax, Inc., Stocks on the move, , Read more ...
Cerus (NASDAQ: CERS ) has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. More news on: Cerus Corporation, Healthcare stocks news, Stocks on the move, Read more ...
Cerus Corporation (Nasdaq: CERS) announced today that it has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, inclu...
Allied Healthcare Products (NASDAQ: AHPI ) +71% . More news on: Allied Healthcare Products, Inc., GAIN Capital Holdings, Inc., Co-Diagnostics, Inc., Stocks on the move, , Read more ...
Cerus Corp. ( CERS ) recently reported their Q4 earnings with a slight miss on EPS and a slight beat on revenue. Cerus finished 2019 with record revenue of $20.9M in Q4 and an annual total of $74.6M; which was at the uppermost end of the company's guidance of $72M-$75M. What is more, the...
Image source: The Motley Fool. Cerus Corporation (NASDAQ: CERS) Q4 2019 Earnings Call Feb 20, 2020 , 4:30 p.m. ET Operator Continue reading
Cerus Corporation (CERS) Q4 2019 Earnings Conference Call February 20, 2020 04:30 PM ET Company Participants Tim Lee - Investor Relations Obi Greenman - President and Chief Executive Officer Kevin Green - Chief Financial Officer Carol Moore - SVP of Regulatory Affairs and Quali...
Cerus Corporation (Nasdaq: CERS) today announced complete financial results for the fourth quarter and year ended December 31, 2019. Recent developments and highlights include: Total fourth quarter revenue of $26.5 million. Record fourth quarter product revenue of $20.9 million,...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...